Scale-up of multidrug-resistant tuberculosis laboratory services, Peru

Emerging Infectious Diseases

Volumn 14, Issue 5, 2008, Pages 701-708

  Shin, Sonya S ^a   Yagui, Martin ^b   Ascencios, Luis ^b   Yale, Gloria ^c   Suarez, Carmen ^c   Quispe, Neyda ^b   Bonilla, Cesar ^c   Blaya, Joaquin ^d   Taylor, Allison ^e   Contreras, Carmen ^f   Cegielski, Peter ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b INSTITUTO NACIONAL DE SALUD   (Peru)

^c Programa de Control de Tuberculosis   (Peru)

^d PARTNERS IN HEALTH   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f SOCIOS EN SALUD   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN;

ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; LABORATORY; MULTIDRUG RESISTANCE; MYCOBACTERIUM; PERU; QUALITY CONTROL; REVIEW; SCALE UP; TUBERCULOSIS;

EID: 45249117894     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1405.070721     Document Type: Review

References (28)

1. Glusker A. Global tuberculosis levels plateau while extensively drug resistant strains increase. BMJ. 2007;334:659.
2. Raviglione MC, Smith IM. XDR tuberculosis - implications for global public health. N Engl J Med. 2007;356:656-9.
3. Ridderhof JC, van Deun A, Nam K, Nayayanan P, Abdul Aziz M. Roles of laboratories and laboratory systems in effective tuberculosis programmes. Bull World Health Organ. 2007;85:354-9.
4. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. 2006. Geneva: The Organization. [cited 2008 Feb 8]. Available from http://whqlibdoc.who.int/publications/2006/9241546956_eng.pdf
5. World Health Organization. The global fund to fight AIDS, tuberculosis and malaria. 2004. Geneva: The Organization [cited 2008 Feb 8]. Available from http://www.who.int/hdp/publications/13h.pdf
6. Gupta R, Cegielski JP, Espinal MA, Henkens M, Kim JY, Lambregts-Van Weezenbeek CS, et al. Increasing transparency in partnerships for health - introducing the Green Light Committee. Trop Med Int Health. 2002;7:970-6.
7. Estrategia sanitaria nacional de control de tuberculosis - Perù. Lima: Informe Operacional; 2005.
8. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999;282:677-86.
9. Getchell WS, Davis CE, Gilman J, Urueta G, Ruiz-Huidobro E, Gilman RH. Basic epidemiology of tuberculosis in Peru: a prevalence study of tuberculin sensitivity in a pueblo joven. Am J Trop Med Hyg. 1992;47:721-9.
10. Madico G, Gilman RH, Checkley W, Cabrera L, Kolstadt I, Kacena K, et al. Community infection ratio as an indicator for tuberculosis control. Lancet. 1995;345:416-9.
11. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim S, Reniero A, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med. 2001;344:1294-303.
12. Netto EM, Dye C, Raviglione MC. Progress in global tuberculosis control 1995-1996, with emphasis on 22 high-incidence countries. Global Monitoring and Surveillance Project. Int J Tuberc Lung Dis. 1999;3:310-20.
13. World Health Organization. Peru set to halve new TB cases every 10 years. Geneva: The Organization. [cited 2008 Feb 8]. Available from http://www.who.int/inf-new/tuber1.htm
14. World Health Organization. Anti-tuberculosis drug resistance in the world report no. 3. Geneva: The Organization. 2004 [cited 2008 Feb 8]. Available from http://www.who.int/tb/publications/who_htm_tb_2004_343/en/index.html
15. Farmer P, Kim JY. Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus." BMJ. 1998;317:671-4.
16. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcantara F, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003;348:119-28.
17. Suarez PG, Floyd K, Portocarrero J, Alarcon E, Rapiti E, Ramos G, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet. 2002;359:1980-9.
18. Yagui M, Perales MT, Asencios L, Vergara L, Suarez C, Yale G, et al. Timely diagnosis of MDR-TB under program conditions: is rapid drug susceptibility testing sufficient? Int J Tuberc Lung Dis. 2006;10:838-43.
19. Coban AY, Birinci A, Ekinci B, Durupinar B. Drug susceptibility testing of Mycobacterium tuberculosis with nitrate reductase assay. Int J Antimicrob Agents. 2004;24:304-6.
20. Solis LA, Shin SS, Han LL, Llanos F, Stowell M, Sloutsky A. Validation of a rapid method for detection of M. tuberculosis resistance to isoniazid and rifampin in Lima, Peru. Int J Tuberc Lung Dis. 2005;9:760-4.
21. Douglas GP, Killam WP, Hochgesang MS, Deula RA, Limbe W, Davis MK. Improving completeness, accuracy and timeliness of HIV voluntary counseling and testing client data in Malawi using touch-screen computers. AMIA Annu Symp Proc 2005:942.
22. Yale G, Bonilla C, Perales M, Contreras C, Yagui M, Shin S, et al. Evaluation of drug susceptibility testing requests under program conditions in Lima, Peru. Presented at International Union Against Tuberculosis and Lung Disease; Paris, France; 2006 Oct 31-Nov 4.
23. Blaya J, Shin S, Yagui M, Yale G, Suarez C, Asencios L, et al. Implementing and evaluating a laboratory information system to optimize the treatment of tuberculosis patients in Peru. Int J Tuber Lung Dis. 2006;10(Suppl. 1):S58-9.
24. Fraser H, Blaya J, Choi S, Bonilla C, Jazayeri D. Evaluating the impact and costs of deploying an electronic medical record system to support TB treatment in Peru. AMIA Annu Symp Proc. 2006:264-8.
25. Bonilla C, Yale G, Perales M, Contreras C, Yagui M, Cegielski P, et al. Distribution of risk factors for MDR-TB in a health district of Lima, Peru (preliminary report). Presented at International Union Against Tuberculosis and Lung Disease; Paris, France; 2006 Oct 31-Nov 4.
26. Moore DA, Evans CA, Gilman RH, Caviedes L, Coronel J, Vivar A, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med. 2006;355:1539-50.
27. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575-80.
28. Cegielski JP, Chin DP, Espinal MA, Frieden TR, Rodriquez Cruz R, Talbot EA, et al. The global tuberculosis situation. Progress and problems in the 20th century, prospects for the 21st century. Infect Dis Clin North Am. 2002;16:1-58. 709-715